468,210 Shares in Kinnate Biopharma Inc. (NASDAQ:KNTE) Purchased by BML Capital Management LLC

BML Capital Management LLC acquired a new position in shares of Kinnate Biopharma Inc. (NASDAQ:KNTE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 468,210 shares of the company’s stock, valued at approximately $1,110,000. Kinnate Biopharma comprises about 0.8% of BML Capital Management LLC’s investment portfolio, making the stock its 21st largest holding.

Several other large investors have also made changes to their positions in KNTE. Citigroup Inc. raised its holdings in Kinnate Biopharma by 53,138.6% in the 3rd quarter. Citigroup Inc. now owns 420,585 shares of the company’s stock valued at $589,000 after acquiring an additional 419,795 shares in the last quarter. Acadian Asset Management LLC grew its position in Kinnate Biopharma by 71.0% during the 3rd quarter. Acadian Asset Management LLC now owns 736,686 shares of the company’s stock worth $1,030,000 after acquiring an additional 305,884 shares during the last quarter. Pale Fire Capital SE lifted its holdings in Kinnate Biopharma by 196.3% during the 3rd quarter. Pale Fire Capital SE now owns 70,174 shares of the company’s stock worth $98,000 after buying an additional 46,492 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Kinnate Biopharma in the 3rd quarter valued at $73,000. Institutional investors and hedge funds own 80.89% of the company’s stock.

Kinnate Biopharma Trading Down 0.4 %

KNTE stock traded down $0.01 during mid-day trading on Wednesday, hitting $2.65. 2,812,200 shares of the company were exchanged, compared to its average volume of 418,678. The business has a 50 day simple moving average of $2.58 and a 200-day simple moving average of $2.22. The stock has a market capitalization of $125.13 million, a PE ratio of -0.95 and a beta of 1.38. Kinnate Biopharma Inc. has a 1-year low of $1.04 and a 1-year high of $7.18.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on KNTE. William Blair downgraded Kinnate Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, February 16th. Stifel Nicolaus raised their price objective on Kinnate Biopharma to $2.59 and gave the stock a “hold” rating in a research note on Monday, February 26th. Finally, Wedbush reaffirmed a “neutral” rating and set a $2.00 price objective on shares of Kinnate Biopharma in a research note on Wednesday, January 17th. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $8.15.

Kinnate Biopharma Company Profile

Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.